BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cilia R, Tunesi S, Marotta G, Cereda E, Siri C, Tesei S, Zecchinelli AL, Canesi M, Mariani CB, Meucci N, Sacilotto G, Zini M, Barichella M, Magnani C, Duga S, Asselta R, Soldà G, Seresini A, Seia M, Pezzoli G, Goldwurm S. Survival and dementia in GBA -associated Parkinson's disease: The mutation matters: Survival in PD- GBA. Ann Neurol 2016;80:662-73. [DOI: 10.1002/ana.24777] [Cited by in Crossref: 162] [Cited by in F6Publishing: 182] [Article Influence: 27.0] [Reference Citation Analysis]
Number Citing Articles
1 Smith LJ, Lee C, Menozzi E, Schapira AHV. Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease. Front Neurol 2022;13:971252. [DOI: 10.3389/fneur.2022.971252] [Reference Citation Analysis]
2 Vieira SRL, Schapira AHV. Glucocerebrosidase mutations and Parkinson disease. J Neural Transm (Vienna) 2022. [PMID: 35932311 DOI: 10.1007/s00702-022-02531-3] [Reference Citation Analysis]
3 Rossi M, Castillo-Torres SA, Merello M. Early motor response to dopamine replacement therapy in Parkinson's disease patients carrying GBA variants. J Neurol Sci 2022;440:120354. [PMID: 35907343 DOI: 10.1016/j.jns.2022.120354] [Reference Citation Analysis]
4 Cong S, Xiang C, Zhang S, Zhang T, Wang H, Cong S. Prevalence and clinical aspects of depression in Parkinson's disease: a systematic review and meta‑analysis of 129 studies. Neurosci Biobehav Rev 2022;:104749. [PMID: 35750224 DOI: 10.1016/j.neubiorev.2022.104749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Venkatesan D, Iyer M, S RW, Narayanasamy A, Kamalakannan S, Valsala Gopalakrishnan A, Vellingiri B. Genotypic-Phenotypic Analysis, Metabolic Profiling and Clinical Correlations in Parkinson's Disease Patients from Tamil Nadu Population, India. J Mol Neurosci 2022. [PMID: 35676593 DOI: 10.1007/s12031-022-02028-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Prasad S, Katta MR, Abhishek S, Sridhar R, Valisekka SS, Hameed M, Kaur J, Walia N. Recent advances in Lewy body dementia: A comprehensive review. Dis Mon 2022;:101441. [PMID: 35690493 DOI: 10.1016/j.disamonth.2022.101441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Nishioka K, Imai Y, Yoshino H, Li Y, Funayama M, Hattori N. Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies. Front Neurol 2022;13:764917. [DOI: 10.3389/fneur.2022.764917] [Reference Citation Analysis]
8 Salles PA, Mata IF, Fernandez HH. Looking back the importance of genetics in a patient with Parkinson disease and deep brain stimulation. Parkinsonism Relat Disord 2022;99:96-8. [PMID: 35461777 DOI: 10.1016/j.parkreldis.2022.04.006] [Reference Citation Analysis]
9 Höglinger G, Schulte C, Jost WH, Storch A, Woitalla D, Krüger R, Falkenburger B, Brockmann K. GBA-associated PD: chances and obstacles for targeted treatment strategies. J Neural Transm (Vienna) 2022. [PMID: 35639160 DOI: 10.1007/s00702-022-02511-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ghatti S, Yoon E, Lopez G, Ehrlich D, Horovitz SG. Imaging and genetics in Parkinson's disease: assessment of the GBA1 mutation. J Neurol 2022. [PMID: 35604467 DOI: 10.1007/s00415-022-11181-0] [Reference Citation Analysis]
11 Filippi M, Balestrino R, Basaia S, Agosta F. Neuroimaging in Glucocerebrosidase-Associated Parkinsonism: A Systematic Review. Mov Disord 2022. [PMID: 35521899 DOI: 10.1002/mds.29047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gegg ME, Menozzi E, Schapira AH. Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments. Neurobiology of Disease 2022;166:105663. [DOI: 10.1016/j.nbd.2022.105663] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
13 Esfandiary A, Finkelstein DI, Voelcker NH, Rudd D. Clinical Sphingolipids Pathway in Parkinson’s Disease: From GCase to Integrated-Biomarker Discovery. Cells 2022;11:1353. [DOI: 10.3390/cells11081353] [Reference Citation Analysis]
14 Smith L, Schapira AHV. GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells 2022;11:1261. [DOI: 10.3390/cells11081261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
15 Galvagnion C, Marlet FR, Cerri S, Schapira AHV, Blandini F, Di Monte DA. Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation. Brain 2022:awab371. [PMID: 35362022 DOI: 10.1093/brain/awab371] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
16 Zheng W, Fan D. Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease: Pathogenesis and Therapeutic Implications. Front Aging Neurosci 2022;14:851135. [DOI: 10.3389/fnagi.2022.851135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Magistrelli L, Contaldi E, Vignaroli F, Gallo S, Colombatto F, Cantello R, Comi C. Immune Response Modifications in the Genetic Forms of Parkinson's Disease: What Do We Know? Int J Mol Sci 2022;23:3476. [PMID: 35408836 DOI: 10.3390/ijms23073476] [Reference Citation Analysis]
18 Carandina A, Lazzeri G, Rodrigues GD, Franco G, Monfrini E, Arienti F, Frattini E, Trezzi I, da Silva Soares PP, Bellocchi C, Furlan L, Montano N, Di Fonzo A, Tobaldini E. Dysautonomia in Parkinson’s Disease: Impact of Glucocerebrosidase Gene Mutations on Cardiovascular Autonomic Control. Front Neurosci 2022;16:842498. [DOI: 10.3389/fnins.2022.842498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Straniero L, Rimoldi V, Monfrini E, Bonvegna S, Melistaccio G, Lake J, Soldà G, Aureli M, Shankaracharya, Keagle P, Foroud T, Landers JE, Blauwendraat C, Zecchinelli A, Cilia R, Di Fonzo A, Pezzoli G, Duga S, Asselta R. Role of Lysosomal Gene Variants in Modulating GBA-Associated Parkinson's Disease Risk. Mov Disord 2022. [PMID: 35262230 DOI: 10.1002/mds.28987] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Szwedo AA, Dalen I, Pedersen KF, Camacho M, Bäckström D, Forsgren L, Tzoulis C, Winder-Rhodes S, Hudson G, Liu G, Scherzer CR, Lawson RA, Yarnall AJ, Williams-Gray CH, Macleod AD, Counsell CE, Tysnes OB, Alves G, Maple-Grødem J; Parkinson's Incidence Cohorts Collaboration. GBA and APOE Impact Cognitive Decline in Parkinson's Disease: A 10-Year Population-Based Study. Mov Disord 2022. [PMID: 35106798 DOI: 10.1002/mds.28932] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
21 Pang SY, Lo RCN, Ho PW, Liu H, Chang EES, Leung C, Malki Y, Choi ZY, Wong WY, Kung MH, Ramsden DB, Ho S. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease. Transl Neurodegener 2022;11. [DOI: 10.1186/s40035-022-00281-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Glinka T, Goldstein O, Kestenbaum M, Cedarbaum JM, Mabrouk OS, Fraser KB, Shirvan JC, Orr-Urtreger A, Mirelman A, Thaler A. Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity. Mov Disord 2022. [PMID: 35064687 DOI: 10.1002/mds.28929] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Peterschmitt MJ, Saiki H, Hatano T, Gasser T, Isaacson SH, Gaemers SJM, Minini P, Saubadu S, Sharma J, Walbillic S, Alcalay RN, Cutter G, Hattori N, Höglinger GU, Marek K, Schapira AHV, Scherzer CR, Simuni T, Giladi N, Sardi SP, Fischer TZ; MOVES-PD Investigators. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial. J Parkinsons Dis 2022;12:557-70. [PMID: 34897099 DOI: 10.3233/JPD-212714] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
24 Li Y, Chen Y, Jiang L, Zhang J, Tong X, Chen D, Le W. Intestinal Inflammation and Parkinson's Disease. Aging Dis 2021;12:2052-68. [PMID: 34881085 DOI: 10.14336/AD.2021.0418] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
25 Lee MJ, Pak K, Kim HK, Nudelman KN, Kim JH, Kim YH, Kang J, Baek MS, Lyoo CH. Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease. NPJ Parkinsons Dis 2021;7:104. [PMID: 34836969 DOI: 10.1038/s41531-021-00250-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Huh YE, Park H, Chiang MSR, Tuncali I, Liu G, Locascio JJ, Shirvan J, Hutten SJ, Rotunno MS, Viel C, Shihabuddin LS, Wang B, Sardi SP, Scherzer CR. Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson's disease enrolled in PPMI. NPJ Parkinsons Dis 2021;7:102. [PMID: 34811369 DOI: 10.1038/s41531-021-00241-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
27 Fan TS, Liu SC, Wu RM. Alpha-Synuclein and Cognitive Decline in Parkinson Disease. Life (Basel) 2021;11:1239. [PMID: 34833115 DOI: 10.3390/life11111239] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
28 Lim JL, Lohmann K, Tan AH, Tay YW, Ibrahim KA, Abdul Aziz Z, Mawardi AS, Puvanarajah SD, Lim TT, Looi I, Ooi JCE, Chia YK, Muthusamy KA, Bauer P, Rolfs A, Klein C, Ahmad-Annuar A, Lim SY. Glucocerebrosidase (GBA) gene variants in a multi-ethnic Asian cohort with Parkinson's disease: mutational spectrum and clinical features. J Neural Transm (Vienna) 2021. [PMID: 34779914 DOI: 10.1007/s00702-021-02421-0] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Salahuddin P, Fatima MT, Uversky VN, Khan RH, Islam Z, Furkan M. The role of amyloids in Alzheimer's and Parkinson's diseases. Int J Biol Macromol 2021;190:44-55. [PMID: 34480905 DOI: 10.1016/j.ijbiomac.2021.08.197] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
30 Vieira SRL, Schapira AHV. Glucocerebrosidase mutations: A paradigm for neurodegeneration pathways. Free Radic Biol Med 2021;175:42-55. [PMID: 34450264 DOI: 10.1016/j.freeradbiomed.2021.08.230] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
31 Elsayed I, Martinez-Carrasco A, Cornejo-Olivas M, Bandres-Ciga S. Mapping the Diverse and Inclusive Future of Parkinson's Disease Genetics and Its Widespread Impact. Genes (Basel) 2021;12:1681. [PMID: 34828286 DOI: 10.3390/genes12111681] [Reference Citation Analysis]
32 Viel C, Clarke J, Kayatekin C, Richards AM, Chiang MSR, Park H, Wang B, Shihabuddin LS, Sardi SP. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Sci Rep 2021;11:20945. [PMID: 34686711 DOI: 10.1038/s41598-021-00404-5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 David FJ, Munoz MJ, Shils JL, Pauciulo MW, Hale PT, Nichols WC, Afshari M, Sani S, Verhagen Metman L, Corcos DM, Pal GD. Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study. Front Neurol 2021;12:723476. [PMID: 34659089 DOI: 10.3389/fneur.2021.723476] [Reference Citation Analysis]
34 Guadagnolo D, Piane M, Torrisi MR, Pizzuti A, Petrucci S. Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings. Front Neurol 2021;12:648588. [PMID: 34630269 DOI: 10.3389/fneur.2021.648588] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
35 Senkevich K, Rudakou U, Gan-Or Z. New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin. Neuropharmacology 2021;202:108822. [PMID: 34626666 DOI: 10.1016/j.neuropharm.2021.108822] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
36 Caminiti SP, Carli G, Avenali M, Blandini F, Perani D. Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations. Mov Disord 2021. [PMID: 34596920 DOI: 10.1002/mds.28818] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
37 Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Glinka T, Goldstein O, Kestenbaum M, Cedarbaum JM, Mabrouk OS, Fraser KB, Shirvan JC, Orr-Urtreger A, Mirelman A, Thaler A. Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity. Mov Disord 2021. [PMID: 34550621 DOI: 10.1002/mds.28792] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
38 Yahalom G, Rigbi A, Israeli-Korn S, Krohn L, Rudakou U, Ruskey JA, Benshimol L, Tsafnat T, Gan-Or Z, Hassin-Baer S, Greenbaum L. Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations. J Parkinsons Dis 2020;10:1123-32. [PMID: 32310186 DOI: 10.3233/JPD-191829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
39 van der Lee SJ, van Steenoven I, van de Beek M, Tesi N, Jansen IE, van Schoor NM, Reinders MJT, Huisman M, Scheltens P, Teunissen CE, Holstege H, van der Flier WM, Lemstra AW. Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. J Alzheimers Dis 2021;83:269-79. [PMID: 34308904 DOI: 10.3233/JAD-210365] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Maple-Grødem J, Paul KC, Dalen I, Ngo KJ, Wong D, Macleod AD, Counsell CE, Bäckström D, Forsgren L, Tysnes OB, Kusters CDJ, Fogel BL, Bronstein JM, Ritz B, Alves G. Lack of Association Between GBA Mutations and Motor Complications in European and American Parkinson's Disease Cohorts. J Parkinsons Dis 2021. [PMID: 34275908 DOI: 10.3233/JPD-212657] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
41 Day JO, Mullin S. The Genetics of Parkinson's Disease and Implications for Clinical Practice. Genes (Basel) 2021;12:1006. [PMID: 34208795 DOI: 10.3390/genes12071006] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
42 Menozzi E, Schapira AHV. Exploring the Genotype-Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers. Front Neurol 2021;12:694764. [PMID: 34248830 DOI: 10.3389/fneur.2021.694764] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
43 Magnusen AF, Hatton SL, Rani R, Pandey MK. Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease. Front Neurol 2021;12:636139. [PMID: 34239490 DOI: 10.3389/fneur.2021.636139] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
44 Abe T, Kuwahara T. Targeting of Lysosomal Pathway Genes for Parkinson's Disease Modification: Insights From Cellular and Animal Models. Front Neurol 2021;12:681369. [PMID: 34194386 DOI: 10.3389/fneur.2021.681369] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
45 Vieira SRL, Morris HR. Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease. Front Neurol 2021;12:679927. [PMID: 34149605 DOI: 10.3389/fneur.2021.679927] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
46 Luukkainen L, Huttula S, Väyrynen H, Helisalmi S, Kytövuori L, Haapasalo A, Hiltunen M, Remes AM, Krüger J. Mutation Analysis of the Genes Associated with Parkinson's Disease in a Finnish Cohort of Early-Onset Dementia. J Alzheimers Dis 2020;76:955-65. [PMID: 32568194 DOI: 10.3233/JAD-200069] [Reference Citation Analysis]
47 Gonzalez-Latapi P, Bayram E, Litvan I, Marras C. Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors. Behav Sci (Basel) 2021;11:74. [PMID: 34068064 DOI: 10.3390/bs11050074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
48 Liu G, Peng J, Liao Z, Locascio JJ, Corvol JC, Zhu F, Dong X, Maple-Grødem J, Campbell MC, Elbaz A, Lesage S, Brice A, Mangone G, Growdon JH, Hung AY, Schwarzschild MA, Hayes MT, Wills AM, Herrington TM, Ravina B, Shoulson I, Taba P, Kõks S, Beach TG, Cormier-Dequaire F, Alves G, Tysnes OB, Perlmutter JS, Heutink P, Amr SS, van Hilten JJ, Kasten M, Mollenhauer B, Trenkwalder C, Klein C, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR; International Genetics of Parkinson Disease Progression (IGPP) Consortium. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. Nat Genet 2021;53:787-93. [PMID: 33958783 DOI: 10.1038/s41588-021-00847-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
49 Sucunza D, Rico AJ, Roda E, Collantes M, González-Aseguinolaza G, Rodríguez-Pérez AI, Peñuelas I, Vázquez A, Labandeira-García JL, Broccoli V, Lanciego JL. Glucocerebrosidase Gene Therapy Induces Alpha-Synuclein Clearance and Neuroprotection of Midbrain Dopaminergic Neurons in Mice and Macaques. Int J Mol Sci 2021;22:4825. [PMID: 34062940 DOI: 10.3390/ijms22094825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
50 Prasuhn J, Brüggemann N. Genotype-driven therapeutic developments in Parkinson's disease. Mol Med 2021;27:42. [PMID: 33874883 DOI: 10.1186/s10020-021-00281-8] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
51 Gan-Or Z, Rao T, Leveille E, Degroot C, Chouinard S, Cicchetti F, Dagher A, Das S, Desautels A, Drouin-Ouellet J, Durcan T, Gagnon JF, Genge A, Karamchandani J, Lafontaine AL, Sun SLW, Langlois M, Levesque M, Melmed C, Panisset M, Parent M, Poline JB, Postuma RB, Pourcher E, Rouleau GA, Sharp M, Monchi O, Dupré N, Fon EA. The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository. J Parkinsons Dis 2020;10:301-13. [PMID: 31868683 DOI: 10.3233/JPD-191775] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
52 Hirano S. Clinical implications for dopaminergic and functional neuroimage research in cognitive symptoms of Parkinson's disease. Mol Med 2021;27:40. [PMID: 33858320 DOI: 10.1186/s10020-021-00301-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
53 Tropea TF, Amari N, Han N, Rick J, Suh E, Akhtar RS, Dahodwala N, Deik A, Gonzalez-Alegre P, Hurtig H, Siderowf A, Spindler M, Stern M, Thenganatt MA, Weintraub D, Willis AW, Van Deerlin V, Chen-Plotkin A. Whole Clinic Research Enrollment in Parkinson's Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study. J Parkinsons Dis 2021;11:757-65. [PMID: 33492247 DOI: 10.3233/JPD-202406] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Li Q, Jing Y, Lun P, Liu X, Sun P. Association of gender and age at onset with glucocerebrosidase associated Parkinson's disease: a systematic review and meta-analysis. Neurol Sci 2021;42:2261-71. [PMID: 33837876 DOI: 10.1007/s10072-021-05230-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
55 Senkevich KA, Kopytova AE, Usenko TS, Emelyanov AK, Pchelina SN. Parkinson's Disease Associated with GBA Gene Mutations: Molecular Aspects and Potential Treatment Approaches. Acta Naturae 2021;13:70-8. [PMID: 34377557 DOI: 10.32607/actanaturae.11031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Reed X, Schumacher-Schuh A, Hu J, Bandres-Ciga S. Advancing Personalized Medicine in Common Forms of Parkinson's Disease through Genetics: Current Therapeutics and the Future of Individualized Management. J Pers Med 2021;11:169. [PMID: 33804504 DOI: 10.3390/jpm11030169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Sosero YL, Yu E, Krohn L, Rudakou U, Mufti K, Ruskey JA, Asayesh F, Laurent SB, Spiegelman D, Fahn S, Waters C, Sardi SP, Bandres-Ciga S, Alcalay RN, Gan-Or Z, Senkevich K. LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease. Neurobiol Aging 2021;103:142.e1-5. [PMID: 33781610 DOI: 10.1016/j.neurobiolaging.2021.02.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
58 Moran EE, Bressman SB, Ortega RA, Raymond D, Nichols WC, Palmese CA, Elango S, Swan M, Shanker V, Perera I, Wang C, Zimmerman ME, Saunders-Pullman R. Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers. Front Neurol 2021;12:635958. [PMID: 33716938 DOI: 10.3389/fneur.2021.635958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
59 Cerri S, Ghezzi C, Ongari G, Croce S, Avenali M, Zangaglia R, Di Monte DA, Valente EM, Blandini F. GBA Mutations Influence the Release and Pathological Effects of Small Extracellular Vesicles from Fibroblasts of Patients with Parkinson's Disease. Int J Mol Sci 2021;22:2215. [PMID: 33672321 DOI: 10.3390/ijms22042215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
60 Avenali M, Cerri S, Ongari G, Ghezzi C, Pacchetti C, Tassorelli C, Valente EM, Blandini F. Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells. Mov Disord 2021;36:1267-72. [PMID: 33617695 DOI: 10.1002/mds.28496] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
61 Howard E, Irwin DJ, Rascovsky K, Nevler N, Shellikeri S, Tropea TF, Spindler M, Deik A, Chen-Plotkin A, Siderowf A, Dahodwala N, Weintraub D, Shaw LM, Trojanowski JQ, Vaishnavi SN, Wolk DA, Mechanic-Hamilton D, Morley JF, Duda JE, Grossman M, Cousins KAQ. Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias. Neurology 2021;96:e1855-64. [PMID: 33593865 DOI: 10.1212/WNL.0000000000011699] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
62 Lerche S, Schulte C, Wurster I, Machetanz G, Roeben B, Zimmermann M, Deuschle C, Hauser AK, Böhringer J, Krägeloh-Mann I, Waniek K, Lachmann I, Petterson XT, Chiang R, Park H, Wang B, Liepelt-Scarfone I, Maetzler W, Galasko D, Scherzer CR, Gasser T, Mielke MM, Hutten SJ, Mollenhauer B, Sardi SP, Berg D, Brockmann K. The Mutation Matters: CSF Profiles of GCase, Sphingolipids, α-Synuclein in PDGBA. Mov Disord 2021;36:1216-28. [PMID: 33547828 DOI: 10.1002/mds.28472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
63 Behl T, Kaur G, Fratila O, Buhas C, Judea-Pusta CT, Negrut N, Bustea C, Bungau S. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegener 2021;10:4. [PMID: 33446243 DOI: 10.1186/s40035-020-00226-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
64 Behl T, Kaur G, Fratila O, Buhas C, Judea-pusta CT, Negrut N, Bustea C, Bungau S. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegener 2021;10. [DOI: 10.1186/s40035-020-00226-x] [Reference Citation Analysis]
65 Picillo M, Scannapieco S, Iavarone A, Ginevrino M, Valente EM, Barone P. Posterior Cortical Atrophy phenotype in a GBA N370S mutation carrier: a case report. BMC Neurol 2021;21:17. [PMID: 33435912 DOI: 10.1186/s12883-020-02023-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 den Heijer JM, van Hilten JJ, Kievit AJA, Bonifati V, Groeneveld GJ. Experience in Genetic Counseling for GBA1 Variants in Parkinson's Disease. Mov Disord Clin Pract 2021;8:33-6. [PMID: 33426156 DOI: 10.1002/mdc3.13098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Daykin EC, Ryan E, Sidransky E. Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes. Mol Genet Metab 2021;132:49-58. [PMID: 33483255 DOI: 10.1016/j.ymgme.2021.01.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
68 Maple-Grødem J, Dalen I, Tysnes OB, Macleod AD, Forsgren L, Counsell CE, Alves G. Association of GBA Genotype With Motor and Functional Decline in Patients With Newly Diagnosed Parkinson Disease. Neurology 2021;96:e1036-44. [PMID: 33443131 DOI: 10.1212/WNL.0000000000011411] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
69 Suárez Torres M, Cano Villagrasa A, Valles González B. Diagnósticos Fonoaudiológicos y Síntomas no Motores en Pacientes con Enfermedad de Parkinson. Rev Areté 2020;20:63-71. [DOI: 10.33881/1657-2513.art20207] [Reference Citation Analysis]
70 Mullin S, Stokholm MG, Hughes D, Mehta A, Parbo P, Hinz R, Pavese N, Brooks DJ, Schapira AHV. Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease. Mov Disord 2021;36:774-9. [PMID: 33278043 DOI: 10.1002/mds.28375] [Cited by in Crossref: 6] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
71 Artusi CA, Lopiano L, Morgante F. Deep Brain Stimulation Selection Criteria for Parkinson's Disease: Time to Go beyond CAPSIT-PD. J Clin Med 2020;9:E3931. [PMID: 33291579 DOI: 10.3390/jcm9123931] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
72 Cherian A, Divya KP. Genetics of Parkinson's disease. Acta Neurol Belg 2020;120:1297-305. [PMID: 32813147 DOI: 10.1007/s13760-020-01473-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
73 Navarro-Romero A, Montpeyó M, Martinez-Vicente M. The Emerging Role of the Lysosome in Parkinson's Disease. Cells 2020;9:E2399. [PMID: 33147750 DOI: 10.3390/cells9112399] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
74 Desplanque M, Bonte MA, Gressier B, Devos D, Chartier-Harlin MC, Belarbi K. Trends in Glucocerebrosides Research: A Systematic Review. Front Physiol 2020;11:558090. [PMID: 33192552 DOI: 10.3389/fphys.2020.558090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Tan MMX, Lawton MA, Jabbari E, Reynolds RH, Iwaki H, Blauwendraat C, Kanavou S, Pollard MI, Hubbard L, Malek N, Grosset KA, Marrinan SL, Bajaj N, Barker RA, Burn DJ, Bresner C, Foltynie T, Wood NW, Williams-Gray CH, Hardy J, Nalls MA, Singleton AB, Williams NM, Ben-Shlomo Y, Hu MTM, Grosset DG, Shoai M, Morris HR. Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. Mov Disord 2021;36:424-33. [PMID: 33111402 DOI: 10.1002/mds.28342] [Cited by in Crossref: 16] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
76 Straniero L, Asselta R, Bonvegna S, Rimoldi V, Melistaccio G, Soldà G, Aureli M, Della Porta M, Lucca U, Di Fonzo A, Zecchinelli A, Pezzoli G, Cilia R, Duga S. The SPID-GBA study: Sex distribution, Penetrance, Incidence, and Dementia in GBA-PD. Neurol Genet 2020;6:e523. [PMID: 33209983 DOI: 10.1212/NXG.0000000000000523] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
77 von Linstow CU, Gan-Or Z, Brundin P. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal. Transl Neurodegener 2020;9:39. [PMID: 33066808 DOI: 10.1186/s40035-020-00218-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
78 Brockmann K. GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds. Front Cell Dev Biol 2020;8:562522. [PMID: 33102473 DOI: 10.3389/fcell.2020.562522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
79 Di Rocco M, Di Fonzo A, Barbato A, Cappellini MD, Carubbi F, Giona F, Giuffrida G, Linari S, Pession A, Quarta A, Scarpa M, Spada M, Strisciuglio P, Andria G. Parkinson's disease in Gaucher disease patients: what's changing in the counseling and management of patients and their relatives? Orphanet J Rare Dis 2020;15:262. [PMID: 32967694 DOI: 10.1186/s13023-020-01529-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Alcalay RN, Wolf P, Chiang MSR, Helesicova K, Zhang XK, Merchant K, Hutten SJ, Scherzer C, Caspell-Garcia C, Blauwendraat C, Foroud T, Nudelman K, Gan-Or Z, Simuni T, Chahine LM, Levy O, Zheng D, Li G, Sardi SP; Parkinson’s Progression Markers Initiative. Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. Ann Clin Transl Neurol 2020;7:1816-30. [PMID: 32888397 DOI: 10.1002/acn3.51164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
81 Greuel A, Trezzi JP, Glaab E, Ruppert MC, Maier F, Jäger C, Hodak Z, Lohmann K, Ma Y, Eidelberg D, Timmermann L, Hiller K, Tittgemeyer M, Drzezga A, Diederich N, Eggers C. GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes. Mov Disord 2020;35:2201-10. [PMID: 32853481 DOI: 10.1002/mds.28225] [Cited by in Crossref: 12] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
82 Phongpreecha T, Cholerton B, Mata IF, Zabetian CP, Poston KL, Aghaeepour N, Tian L, Quinn JF, Chung KA, Hiller AL, Hu SC, Edwards KL, Montine TJ. Multivariate prediction of dementia in Parkinson's disease. NPJ Parkinsons Dis 2020;6:20. [PMID: 32885039 DOI: 10.1038/s41531-020-00121-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
83 Migdalska-Richards A, Wegrzynowicz M, Harrison IF, Verona G, Bellotti V, Spillantini MG, Schapira AHV. L444P Gba1 mutation increases formation and spread of α-synuclein deposits in mice injected with mouse α-synuclein pre-formed fibrils. PLoS One 2020;15:e0238075. [PMID: 32833982 DOI: 10.1371/journal.pone.0238075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
84 Balestrino R, Tunesi S, Tesei S, Lopiano L, Zecchinelli AL, Goldwurm S. Penetrance of Glucocerebrosidase (GBA) Mutations in Parkinson's Disease: A Kin Cohort Study. Mov Disord 2020;35:2111-4. [PMID: 32767585 DOI: 10.1002/mds.28200] [Cited by in Crossref: 9] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
85 Bonner N, Bozzi S, Morgan L, Mason B, Peterschmitt MJ, Fischer TZ, Arbuckle R, Reaney M. Patients' experiences of Parkinson's disease: a qualitative study in glucocerebrosidase and idiopathic Parkinson's disease. J Patient Rep Outcomes 2020;4:65. [PMID: 32757092 DOI: 10.1186/s41687-020-00230-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
86 Marras C, Chaudhuri KR, Titova N, Mestre TA. Therapy of Parkinson's Disease Subtypes. Neurotherapeutics 2020;17:1366-77. [PMID: 32749651 DOI: 10.1007/s13311-020-00894-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
87 Blumenreich S, Barav OB, Jenkins BJ, Futerman AH. Lysosomal Storage Disorders Shed Light on Lysosomal Dysfunction in Parkinson's Disease. Int J Mol Sci 2020;21:E4966. [PMID: 32674335 DOI: 10.3390/ijms21144966] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
88 Petrucci S, Ginevrino M, Trezzi I, Monfrini E, Ricciardi L, Albanese A, Avenali M, Barone P, Bentivoglio AR, Bonifati V, Bove F, Bonanni L, Brusa L, Cereda C, Cossu G, Criscuolo C, Dati G, De Rosa A, Eleopra R, Fabbrini G, Fadda L, Garbellini M, Minafra B, Onofrj M, Pacchetti C, Palmieri I, Pellecchia MT, Petracca M, Picillo M, Pisani A, Vallelunga A, Zangaglia R, Di Fonzo A, Morgante F, Valente EM; ITA-GENE-PD Study Group. GBA-Related Parkinson's Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort. Mov Disord 2020;35:2106-11. [PMID: 32658388 DOI: 10.1002/mds.28195] [Cited by in Crossref: 17] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
89 den Heijer JM, Cullen VC, Quadri M, Schmitz A, Hilt DC, Lansbury P, Berendse HW, van de Berg WDJ, de Bie RMA, Boertien JM, Boon AJW, Contarino MF, van Hilten JJ, Hoff JI, van Mierlo T, Munts AG, van der Plas AA, Ponsen MM, Baas F, Majoor-Krakauer D, Bonifati V, van Laar T, Groeneveld GJ. A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands. Mov Disord 2020;35:1667-74. [PMID: 32618053 DOI: 10.1002/mds.28112] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
90 Krohn L, Ruskey JA, Rudakou U, Leveille E, Asayesh F, Hu MTM, Arnulf I, Dauvilliers Y, Högl B, Stefani A, Monaca CC, Abril B, Plazzi G, Antelmi E, Ferini-Strambi L, Heidbreder A, Boeve BF, Espay AJ, De Cock VC, Mollenhauer B, Sixel-Döring F, Trenkwalder C, Sonka K, Kemlink D, Figorilli M, Puligheddu M, Dijkstra F, Viaene M, Oertel W, Toffoli M, Gigli GL, Valente M, Gagnon JF, Desautels A, Montplaisir JY, Postuma RB, Rouleau GA, Gan-Or Z. GBA variants in REM sleep behavior disorder: A multicenter study. Neurology 2020;95:e1008-16. [PMID: 32591474 DOI: 10.1212/WNL.0000000000010042] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
91 Schierding W, Farrow S, Fadason T, Graham OEE, Pitcher TL, Qubisi S, Davidson AJ, Perry JK, Anderson TJ, Kennedy MA, Cooper A, O'Sullivan JM. Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset. Mov Disord 2020;35:1346-56. [PMID: 32557794 DOI: 10.1002/mds.28144] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
92 Polissidis A, Petropoulou-Vathi L, Nakos-Bimpos M, Rideout HJ. The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson's Disease. Biomolecules 2020;10:E912. [PMID: 32560161 DOI: 10.3390/biom10060912] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
93 Huh YE, Chiang MSR, Locascio JJ, Liao Z, Liu G, Choudhury K, Kuras YI, Tuncali I, Videnovic A, Hunt AL, Schwarzschild MA, Hung AY, Herrington TM, Hayes MT, Hyman BT, Wills AM, Gomperts SN, Growdon JH, Sardi SP, Scherzer CR. β-Glucocerebrosidase activity in GBA-linked Parkinson disease: The type of mutation matters. Neurology 2020;95:e685-96. [PMID: 32540937 DOI: 10.1212/WNL.0000000000009989] [Cited by in Crossref: 7] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
94 Aasly JO. Long-Term Outcomes of Genetic Parkinson's Disease. J Mov Disord 2020;13:81-96. [PMID: 32498494 DOI: 10.14802/jmd.19080] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
95 Lerche S, Wurster I, Röben B, Zimmermann M, Machetanz G, Wiethoff S, Dehnert M, Rietschel L, Riebenbauer B, Deuschle C, Stransky E, Lieplt‐scarfone I, Gasser T, Brockmann K. CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories. Mov Disord 2020;35:1138-44. [DOI: 10.1002/mds.28056] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
96 Tan MMX, Malek N, Lawton MA, Hubbard L, Pittman AM, Joseph T, Hehir J, Swallow DMA, Grosset KA, Marrinan SL, Bajaj N, Barker RA, Burn DJ, Bresner C, Foltynie T, Hardy J, Wood N, Ben-Shlomo Y, Grosset DG, Williams NM, Morris HR. Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study. Brain 2019;142:2828-44. [PMID: 31324919 DOI: 10.1093/brain/awz191] [Cited by in Crossref: 26] [Cited by in F6Publishing: 37] [Article Influence: 13.0] [Reference Citation Analysis]
97 Omer N, Giladi N, Gurevich T, Bar-Shira A, Gana-Weisz M, Goldstein O, Kestenbaum M, Cedarbaum JM, Orr-Urtreger A, Mirelman A, Thaler A. A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease. Mov Disord 2020;35:1249-53. [PMID: 32353202 DOI: 10.1002/mds.28066] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
98 Avenali M, Blandini F, Cerri S. Glucocerebrosidase Defects as a Major Risk Factor for Parkinson's Disease. Front Aging Neurosci 2020;12:97. [PMID: 32372943 DOI: 10.3389/fnagi.2020.00097] [Cited by in Crossref: 17] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
99 Ryan E, Seehra G, Sharma P, Sidransky E. GBA1-associated parkinsonism: new insights and therapeutic opportunities. Curr Opin Neurol 2019;32:589-96. [PMID: 31188151 DOI: 10.1097/WCO.0000000000000715] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
100 Stoker TB, Camacho M, Winder-Rhodes S, Liu G, Scherzer CR, Foltynie T, Evans J, Breen DP, Barker RA, Williams-Gray CH. Impact of GBA1 variants on long-term clinical progression and mortality in incident Parkinson's disease. J Neurol Neurosurg Psychiatry 2020;91:695-702. [PMID: 32303560 DOI: 10.1136/jnnp-2020-322857] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
101 Stoker TB, Camacho M, Winder-Rhodes S, Liu G, Scherzer CR, Foltynie T, Barker RA, Williams-Gray CH. A common polymorphism in SNCA is associated with accelerated motor decline in GBA-Parkinson's disease. J Neurol Neurosurg Psychiatry 2020;91:673-4. [PMID: 32241921 DOI: 10.1136/jnnp-2019-322210] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
102 Senkevich K, Gan-or Z. Autophagy lysosomal pathway dysfunction in Parkinson's disease; evidence from human genetics. Parkinsonism & Related Disorders 2020;73:60-71. [DOI: 10.1016/j.parkreldis.2019.11.015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
103 Paolini Paoletti F, Gaetani L, Parnetti L. Molecular profiling in Parkinsonian syndromes: CSF biomarkers. Clin Chim Acta 2020;506:55-66. [PMID: 32142717 DOI: 10.1016/j.cca.2020.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
104 Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, Strafella AP, Singleton AB, Barker RA, Kieburtz K, Olanow CW, Lozano A, Kordower JH, Cedarbaum JM, Brundin P, Standaert DG, Lang AE. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology 2020;94:481-94. [PMID: 32102975 DOI: 10.1212/WNL.0000000000009107] [Cited by in Crossref: 37] [Cited by in F6Publishing: 47] [Article Influence: 18.5] [Reference Citation Analysis]
105 Paciotti S, Albi E, Parnetti L, Beccari T. Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson's Disease. J Clin Med 2020;9:E594. [PMID: 32098196 DOI: 10.3390/jcm9020594] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
106 Simuni T, Brumm MC, Uribe L, Caspell-Garcia C, Coffey CS, Siderowf A, Alcalay RN, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Nudelman K, Tosun-Turgut D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Bressman S, Marek K; Parkinson's Progression Markers Initiative Investigators. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. Mov Disord 2020;35:833-44. [PMID: 32073681 DOI: 10.1002/mds.27989] [Cited by in Crossref: 12] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
107 Jones S, Torsney KM, Scourfield L, Berryman K, Henderson EJ. Neuropsychiatric symptoms in Parkinson's disease: aetiology, diagnosis and treatment. BJPsych advances 2020;26:333-42. [DOI: 10.1192/bja.2019.79] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
108 Gera A, O'Keefe JA, Ouyang B, Liu Y, Ruehl S, Buder M, Joyce J, Purcell N, Pal G. Gait asymmetry in glucocerebrosidase mutation carriers with Parkinson's disease. PLoS One 2020;15:e0226494. [PMID: 31978134 DOI: 10.1371/journal.pone.0226494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
109 Marotta N, Kim S, Krainc D. Organoid and pluripotent stem cells in Parkinson's disease modeling: an expert view on their value to drug discovery. Expert Opin Drug Discov 2020;15:427-41. [PMID: 31899983 DOI: 10.1080/17460441.2020.1703671] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
110 Zhang Y, Chen J, Xu C, Feng J, Li J. Effects of glucocerebrosidase gene polymorphisms and mutations on the risk of Parkinson's disease dementia: A meta-analysis. Neurosci Lett 2020;714:134544. [PMID: 31672490 DOI: 10.1016/j.neulet.2019.134544] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
111 Schindlbeck KA, Vo A, Nguyen N, Tang CC, Niethammer M, Dhawan V, Brandt V, Saunders-Pullman R, Bressman SB, Eidelberg D. LRRK2 and GBA Variants Exert Distinct Influences on Parkinson's Disease-Specific Metabolic Networks. Cereb Cortex 2020;30:2867-78. [PMID: 31813991 DOI: 10.1093/cercor/bhz280] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
112 Leonard H, Blauwendraat C, Krohn L, Faghri F, Iwaki H, Ferguson G, Day-Williams AG, Stone DJ, Singleton AB, Nalls MA, Gan-Or Z; International Parkinson's Disease Genomic Consortium (IPDGC). Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson's disease. J Med Genet 2020;57:331-8. [PMID: 31784483 DOI: 10.1136/jmedgenet-2019-106283] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
113 Gan-Or Z, Alcalay RN, Makarious MB, Scholz SW, Blauwendraat C; International Parkinson's Disease Genomics Consortium (IPDGC). Classification of GBA Variants and Their Effects in Synucleinopathies. Mov Disord 2019;34:1581-2. [PMID: 31769092 DOI: 10.1002/mds.27803] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Alcalay RN, Kehoe C, Shorr E, Battista R, Hall A, Simuni T, Marder K, Wills AM, Naito A, Beck JC, Schwarzschild MA, Nance M. Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. Genet Med 2020;22:574-80. [PMID: 31680121 DOI: 10.1038/s41436-019-0684-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
115 Lerche S, Wurster I, Roeben B, Zimmermann M, Riebenbauer B, Deuschle C, Hauser A, Schulte C, Berg D, Maetzler W, Waniek K, Lachmann I, Liepelt‐scarfone I, Gasser T, Brockmann K. Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha‐Synuclein Profiles. Mov Disord 2020;35:495-9. [DOI: 10.1002/mds.27884] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
116 Xicoy H, Peñuelas N, Vila M, Laguna A. Autophagic- and Lysosomal-Related Biomarkers for Parkinson's Disease: Lights and Shadows. Cells 2019;8:E1317. [PMID: 31731485 DOI: 10.3390/cells8111317] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
117 Johnson PH, Weinreb NJ, Cloyd JC, Tuite PJ, Kartha RV. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies. Mol Genet Metab 2020;129:35-46. [PMID: 31761523 DOI: 10.1016/j.ymgme.2019.10.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
118 Shihabuddin LS, Brundin P, Greenamyre JT, Stephenson D, Sardi SP. New Frontiers in Parkinson's Disease: From Genetics to the Clinic. J Neurosci 2018;38:9375-82. [PMID: 30381429 DOI: 10.1523/JNEUROSCI.1666-18.2018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
119 Ligaard J, Sannæs J, Pihlstrøm L. Deep brain stimulation and genetic variability in Parkinson's disease: a review of the literature. NPJ Parkinsons Dis 2019;5:18. [PMID: 31508488 DOI: 10.1038/s41531-019-0091-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
120 Foffani G, Trigo‐damas I, Pineda‐pardo JA, Blesa J, Rodríguez‐rojas R, Martínez‐fernández R, Obeso JA. Focused ultrasound in Parkinson's disease: A twofold path toward disease modification. Mov Disord 2019;34:1262-73. [DOI: 10.1002/mds.27805] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
121 Mehanna R, Jankovic J. Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism & Related Disorders 2019;65:39-48. [DOI: 10.1016/j.parkreldis.2019.06.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
122 Ahmadi Rastegar D, Ho N, Halliday GM, Dzamko N. Parkinson's progression prediction using machine learning and serum cytokines. NPJ Parkinsons Dis 2019;5:14. [PMID: 31372494 DOI: 10.1038/s41531-019-0086-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
123 Savitt D, Jankovic J. Targeting α-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics. Drugs 2019;79:797-810. [PMID: 30982161 DOI: 10.1007/s40265-019-01104-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 45] [Article Influence: 10.3] [Reference Citation Analysis]
124 Farfel-Becker T, Do J, Tayebi N, Sidransky E. Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse? Trends Neurosci 2019;42:631-43. [PMID: 31288942 DOI: 10.1016/j.tins.2019.05.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
125 Baden P, Yu C, Deleidi M. Insights into GBA Parkinson's disease pathology and therapy with induced pluripotent stem cell model systems. Neurobiology of Disease 2019;127:1-12. [DOI: 10.1016/j.nbd.2019.01.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
126 Rizzone MG, Martone T, Balestrino R, Lopiano L. Genetic background and outcome of Deep Brain Stimulation in Parkinson's disease. Parkinsonism & Related Disorders 2019;64:8-19. [DOI: 10.1016/j.parkreldis.2018.08.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
127 Ng ASL, Tan YJ, Zhao Y, Saffari SE, Lu Z, Ng EYL, Ng SYE, Chia NSY, Setiawan F, Xu Z, Tay KY, Au WL, Tan LCS, Tan EK. SNCA Rep1 promoter variability influences cognition in Parkinson's disease. Mov Disord 2019;34:1232-6. [PMID: 31234238 DOI: 10.1002/mds.27768] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
128 Lerche S, Machetanz G, Wurster I, Roeben B, Zimmermann M, Pilotto A, Preische O, Stransky E, Deuschle C, Hauser A, Schulte C, Lachmann I, Waniek K, Gasser T, Berg D, Maetzler W, Brockmann K. Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alpha‐synuclein profile. Mov Disord 2019;34:1069-73. [DOI: 10.1002/mds.27731] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
129 Lim SY, Tan AH, Ahmad-Annuar A, Klein C, Tan LCS, Rosales RL, Bhidayasiri R, Wu YR, Shang HF, Evans AH, Pal PK, Hattori N, Tan CT, Jeon B, Tan EK, Lang AE. Parkinson's disease in the Western Pacific Region. Lancet Neurol 2019;18:865-79. [PMID: 31175000 DOI: 10.1016/S1474-4422(19)30195-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 51] [Article Influence: 14.3] [Reference Citation Analysis]
130 Riboldi GM, Di Fonzo AB. GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells 2019;8:E364. [PMID: 31010158 DOI: 10.3390/cells8040364] [Cited by in Crossref: 58] [Cited by in F6Publishing: 83] [Article Influence: 19.3] [Reference Citation Analysis]
131 Senkevich KA, Miliukhina IV, Pchelina SN. [The genetic predictors of cognitive impairment in Parkinson's disease]. Zh Nevrol Psikhiatr Im S S Korsakova 2018;118:109-17. [PMID: 30251988 DOI: 10.17116/jnevro2018118081109] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Paciotti S, Gatticchi L, Beccari T, Parnetti L. Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies. Clin Chim Acta 2019;495:13-24. [PMID: 30922855 DOI: 10.1016/j.cca.2019.03.1627] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
133 Hertz E, Thörnqvist M, Holmberg B, Machaczka M, Sidransky E, Svenningsson P. First Clinicogenetic Description of Parkinson's Disease Related to GBA Mutation S107L. Mov Disord Clin Pract 2019;6:254-8. [PMID: 30949558 DOI: 10.1002/mdc3.12743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
134 Louis ED, Joyce JL, Cosentino S. Mind the gaps: What we don't know about cognitive impairment in essential tremor. Parkinsonism Relat Disord 2019;63:10-9. [PMID: 30876840 DOI: 10.1016/j.parkreldis.2019.02.038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
135 Sardi SP, Simuni T. New Era in disease modification in Parkinson's disease: Review of genetically targeted therapeutics. Parkinsonism & Related Disorders 2019;59:32-8. [DOI: 10.1016/j.parkreldis.2018.10.025] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
136 Standaert DG. What would Dr. James parkinson think today? Mutations in beta-glucocerebrosidase and risk of Parkinson's disease. Mov Disord 2017;32:1341-2. [PMID: 29068500 DOI: 10.1002/mds.27206] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
137 Blandini F, Cilia R, Cerri S, Pezzoli G, Schapira AHV, Mullin S, Lanciego JL. Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. Mov Disord 2019;34:9-21. [PMID: 30589955 DOI: 10.1002/mds.27583] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 10.3] [Reference Citation Analysis]
138 Yahalom G, Greenbaum L, Israeli-Korn S, Fay-Karmon T, Livneh V, Ruskey JA, Roncière L, Alam A, Gan-Or Z, Hassin-Baer S. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations. Parkinsonism Relat Disord 2019;62:179-84. [PMID: 30573413 DOI: 10.1016/j.parkreldis.2018.12.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 7.5] [Reference Citation Analysis]
139 Mullin S, Hughes D, Mehta A, Schapira AHV. Neurological effects of glucocerebrosidase gene mutations. Eur J Neurol 2019;26:388-e29. [PMID: 30315684 DOI: 10.1111/ene.13837] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
140 Mus L, Siani F, Giuliano C, Ghezzi C, Cerri S, Blandini F. Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity. Neurobiol Dis 2019;124:289-96. [PMID: 30521842 DOI: 10.1016/j.nbd.2018.12.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
141 Li H, Ham A, Ma TC, Kuo SH, Kanter E, Kim D, Ko HS, Quan Y, Sardi SP, Li A, Arancio O, Kang UJ, Sulzer D, Tang G. Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations. Autophagy 2019;15:113-30. [PMID: 30160596 DOI: 10.1080/15548627.2018.1509818] [Cited by in Crossref: 69] [Cited by in F6Publishing: 93] [Article Influence: 17.3] [Reference Citation Analysis]
142 Limphaibool N, Iwanowski P, Holstad MJV, Perkowska K. Parkinsonism in Inherited Metabolic Disorders: Key Considerations and Major Features. Front Neurol 2018;9:857. [PMID: 30369906 DOI: 10.3389/fneur.2018.00857] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
143 Cai Y, Wan J. Competing Endogenous RNA Regulations in Neurodegenerative Disorders: Current Challenges and Emerging Insights. Front Mol Neurosci 2018;11:370. [PMID: 30344479 DOI: 10.3389/fnmol.2018.00370] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
144 Thaler A, Kozlovski T, Gurevich T, Bar-Shira A, Gana-Weisz M, Orr-Urtreger A, Giladi N, Mirelman A. Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes. Mov Disord 2018;33:1656-60. [PMID: 30288804 DOI: 10.1002/mds.27490] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
145 Zhang Y, Shu L, Zhou X, Pan H, Xu Q, Guo J, Tang B, Sun Q. A Meta-Analysis of GBA-Related Clinical Symptoms in Parkinson's Disease. Parkinsons Dis 2018;2018:3136415. [PMID: 30363648 DOI: 10.1155/2018/3136415] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
146 Zimmermann M, Gaenslen A, Prahl K, Srulijes K, Hauser AK, Schulte C, Csoti I, Berg D, Brockmann K. Patient's perception: shorter and more severe prodromal phase in GBA-associated PD. Eur J Neurol 2019;26:694-8. [PMID: 30107068 DOI: 10.1111/ene.13776] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
147 Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, Simuni T, Weintraub D; Parkinson’s Progression Markers Initiative. Cognition among individuals along a spectrum of increased risk for Parkinson's disease. PLoS One 2018;13:e0201964. [PMID: 30125297 DOI: 10.1371/journal.pone.0201964] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
148 Ruskey JA, Zhou S, Santiago R, Franche LA, Alam A, Roncière L, Spiegelman D, Fon EA, Trempe JF, Kalia LV, Postuma RB, Dupre N, Rivard GE, Assouline S, Amato D, Gan-Or Z. The GBA p.Trp378Gly mutation is a probable French-Canadian founder mutation causing Gaucher disease and synucleinopathies. Clin Genet 2018;94:339-45. [PMID: 29920646 DOI: 10.1111/cge.13405] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
149 Franco R, Sánchez-Arias JA, Navarro G, Lanciego JL. Glucocerebrosidase Mutations and Synucleinopathies. Potential Role of Sterylglucosides and Relevance of Studying Both GBA1 and GBA2 Genes. Front Neuroanat 2018;12:52. [PMID: 30002620 DOI: 10.3389/fnana.2018.00052] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
150 Gan-Or Z, Liong C, Alcalay RN. GBA-Associated Parkinson's Disease and Other Synucleinopathies. Curr Neurol Neurosci Rep 2018;18:44. [PMID: 29884970 DOI: 10.1007/s11910-018-0860-4] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 11.3] [Reference Citation Analysis]
151 Moors TE, Paciotti S, Ingrassia A, Quadri M, Breedveld G, Tasegian A, Chiasserini D, Eusebi P, Duran-Pacheco G, Kremer T, Calabresi P, Bonifati V, Parnetti L, Beccari T, van de Berg WDJ. Characterization of Brain Lysosomal Activities in GBA-Related and Sporadic Parkinson's Disease and Dementia with Lewy Bodies. Mol Neurobiol 2019;56:1344-55. [PMID: 29948939 DOI: 10.1007/s12035-018-1090-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 65] [Article Influence: 13.0] [Reference Citation Analysis]
152 Ruskey JA, Greenbaum L, Roncière L, Alam A, Spiegelman D, Liong C, Levy OA, Waters C, Fahn S, Marder KS, Chung W, Yahalom G, Israeli-Korn S, Livneh V, Fay-Karmon T, Alcalay RN, Hassin-Baer S, Gan-Or Z. Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease. Eur J Med Genet 2019;62:65-9. [PMID: 29842932 DOI: 10.1016/j.ejmg.2018.05.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
153 Lunde KA, Chung J, Dalen I, Pedersen KF, Linder J, Domellöf ME, Elgh E, Macleod AD, Tzoulis C, Larsen JP, Tysnes OB, Forsgren L, Counsell CE, Alves G, Maple-Grødem J. Association of glucocerebrosidase polymorphisms and mutations with dementia in incident Parkinson's disease. Alzheimers Dement 2018;14:1293-301. [PMID: 29792872 DOI: 10.1016/j.jalz.2018.04.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
154 Thaler A, Bregman N, Gurevich T, Shiner T, Dror Y, Zmira O, Gan-Or Z, Bar-Shira A, Gana-Weisz M, Orr-Urtreger A, Giladi N, Mirelman A. Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene. Parkinsonism Relat Disord 2018;55:45-9. [PMID: 29784561 DOI: 10.1016/j.parkreldis.2018.05.009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 49] [Article Influence: 8.5] [Reference Citation Analysis]
155 O'Regan G, deSouza RM, Balestrino R, Schapira AH. Glucocerebrosidase Mutations in Parkinson Disease. J Parkinsons Dis 2017;7:411-22. [PMID: 28598856 DOI: 10.3233/JPD-171092] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 15.8] [Reference Citation Analysis]
156 Sardi SP, Cedarbaum JM, Brundin P. Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic. Mov Disord 2018;33:684-96. [PMID: 29704272 DOI: 10.1002/mds.27414] [Cited by in Crossref: 89] [Cited by in F6Publishing: 90] [Article Influence: 22.3] [Reference Citation Analysis]
157 Gary SE, Ryan E, Steward AM, Sidransky E. Recent advances in the diagnosis and management of Gaucher disease. Expert Rev Endocrinol Metab 2018;13:107-18. [PMID: 30058864 DOI: 10.1080/17446651.2018.1445524] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
158 Deng H, Wang P, Jankovic J. The genetics of Parkinson disease. Ageing Res Rev 2018;42:72-85. [PMID: 29288112 DOI: 10.1016/j.arr.2017.12.007] [Cited by in Crossref: 250] [Cited by in F6Publishing: 227] [Article Influence: 62.5] [Reference Citation Analysis]
159 Gámez-Valero A, Iranzo A, Serradell M, Vilas D, Santamaria J, Gaig C, Álvarez R, Ariza A, Tolosa E, Beyer K. Glucocerebrosidase gene variants are accumulated in idiopathic REM sleep behavior disorder. Parkinsonism Relat Disord 2018;50:94-8. [PMID: 29487000 DOI: 10.1016/j.parkreldis.2018.02.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
160 Gegg ME, Schapira AHV. The role of glucocerebrosidase in Parkinson disease pathogenesis. FEBS J 2018;285:3591-603. [DOI: 10.1111/febs.14393] [Cited by in Crossref: 66] [Cited by in F6Publishing: 78] [Article Influence: 16.5] [Reference Citation Analysis]
161 Jellinger KA. Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.J Neural Transm (Vienna). 2018;125:615-650. [PMID: 29222591 DOI: 10.1007/s00702-017-1821-9] [Cited by in Crossref: 93] [Cited by in F6Publishing: 106] [Article Influence: 18.6] [Reference Citation Analysis]
162 Helley MP, Pinnell J, Sportelli C, Tieu K. Mitochondria: A Common Target for Genetic Mutations and Environmental Toxicants in Parkinson's Disease. Front Genet 2017;8:177. [PMID: 29204154 DOI: 10.3389/fgene.2017.00177] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
163 Straniero L, Rimoldi V, Samarani M, Goldwurm S, Di Fonzo A, Krüger R, Deleidi M, Aureli M, Soldà G, Duga S, Asselta R. The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p. Sci Rep 2017;7:12702. [PMID: 28983119 DOI: 10.1038/s41598-017-12973-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 6.6] [Reference Citation Analysis]
164 Vergouw LJ, van Steenoven I, van de Berg WD, Teunissen CE, van Swieten JC, Bonifati V, Lemstra AW, de Jong FJ. An update on the genetics of dementia with Lewy bodies. Parkinsonism & Related Disorders 2017;43:1-8. [DOI: 10.1016/j.parkreldis.2017.07.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
165 Parnetti L, Paciotti S, Eusebi P, Dardis A, Zampieri S, Chiasserini D, Tasegian A, Tambasco N, Bembi B, Calabresi P, Beccari T. Cerebrospinal fluid β-glucocerebrosidase activity is reduced in parkinson's disease patients. Mov Disord 2017;32:1423-31. [PMID: 28843015 DOI: 10.1002/mds.27136] [Cited by in Crossref: 63] [Cited by in F6Publishing: 77] [Article Influence: 12.6] [Reference Citation Analysis]
166 Aflaki E, Westbroek W, Sidransky E. The Complicated Relationship between Gaucher Disease and Parkinsonism: Insights from a Rare Disease. Neuron 2017;93:737-46. [PMID: 28231462 DOI: 10.1016/j.neuron.2017.01.018] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 18.2] [Reference Citation Analysis]
167 Adler CH, Beach TG, Shill HA, Caviness JN, Driver-Dunckley E, Sabbagh MN, Patel A, Sue LI, Serrano G, Jacobson SA, Davis K, Belden CM, Dugger BN, Paciga SA, Winslow AR, Hirst WD, Hentz JG. GBA mutations in Parkinson disease: earlier death but similar neuropathological features. Eur J Neurol 2017;24:1363-8. [PMID: 28834018 DOI: 10.1111/ene.13395] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
168 García-Sanz P, Orgaz L, Bueno-Gil G, Espadas I, Rodríguez-Traver E, Kulisevsky J, Gutierrez A, Dávila JC, González-Polo RA, Fuentes JM, Mir P, Vicario C, Moratalla R. N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease. Mov Disord 2017;32:1409-22. [PMID: 28779532 DOI: 10.1002/mds.27119] [Cited by in Crossref: 42] [Cited by in F6Publishing: 54] [Article Influence: 8.4] [Reference Citation Analysis]
169 Moran EE, Wang C, Katz M, Ozelius L, Schwartz A, Pavlovic J, Ortega RA, Lipton RB, Zimmerman ME, Saunders-Pullman R. Cognitive and motor functioning in elderly glucocerebrosidase mutation carriers. Neurobiol Aging 2017;58:239.e1-7. [PMID: 28728889 DOI: 10.1016/j.neurobiolaging.2017.06.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
170 Gwinn K, David KK, Swanson-Fischer C, Albin R, Hillaire-Clarke CS, Sieber BA, Lungu C, Bowman FD, Alcalay RN, Babcock D, Dawson TM, Dewey RB Jr, Foroud T, German D, Huang X, Petyuk V, Potashkin JA, Saunders-Pullman R, Sutherland M, Walt DR, West AB, Zhang J, Chen-Plotkin A, Scherzer CR, Vaillancourt DE, Rosenthal LS. Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program. Biomark Med 2017;11:451-73. [PMID: 28644039 DOI: 10.2217/bmm-2016-0370] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
171 Farotti L, Paciotti S, Tasegian A, Eusebi P, Parnetti L. Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease. Expert Rev Mol Diagn 2017;17:771-80. [PMID: 28604235 DOI: 10.1080/14737159.2017.1341312] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
172 Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR; HBS., CamPaIGN., PICNICS., PROPARK., PSG., DIGPD., PDBP. Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. Lancet Neurol 2017;16:620-9. [PMID: 28629879 DOI: 10.1016/S1474-4422(17)30122-9] [Cited by in Crossref: 81] [Cited by in F6Publishing: 88] [Article Influence: 16.2] [Reference Citation Analysis]
173 Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag A, Lang AE. Parkinson disease. Nat Rev Dis Primers 2017;3. [DOI: 10.1038/nrdp.2017.13] [Cited by in Crossref: 1345] [Cited by in F6Publishing: 1572] [Article Influence: 269.0] [Reference Citation Analysis]
174 Fereshtehnejad S, Postuma RB. Subtypes of Parkinson’s Disease: What Do They Tell Us About Disease Progression? Curr Neurol Neurosci Rep 2017;17. [DOI: 10.1007/s11910-017-0738-x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 68] [Article Influence: 11.4] [Reference Citation Analysis]
175 Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, Ballard C. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017;13:217-231. [PMID: 28257128 DOI: 10.1038/nrneurol.2017.27] [Cited by in Crossref: 382] [Cited by in F6Publishing: 408] [Article Influence: 76.4] [Reference Citation Analysis]
176 Fagan ES, Pihlstrøm L. Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature. Eur J Neurol 2017;24:561-e20. [DOI: 10.1111/ene.13258] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
177 Sardi SP, Viel C, Clarke J, Treleaven CM, Richards AM, Park H, Olszewski MA, Dodge JC, Marshall J, Makino E, Wang B, Sidman RL, Cheng SH, Shihabuddin LS. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models. Proc Natl Acad Sci U S A 2017;114:2699-704. [PMID: 28223512 DOI: 10.1073/pnas.1616152114] [Cited by in Crossref: 99] [Cited by in F6Publishing: 115] [Article Influence: 19.8] [Reference Citation Analysis]
178 Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A, Rose C, Billette de Villemeur T, Berger MG. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci 2017;18:E441. [PMID: 28218669 DOI: 10.3390/ijms18020441] [Cited by in Crossref: 232] [Cited by in F6Publishing: 242] [Article Influence: 46.4] [Reference Citation Analysis]
179 Strafella AP, Bohnen NI, Perlmutter JS, Eidelberg D, Pavese N, Van Eimeren T, Piccini P, Politis M, Thobois S, Ceravolo R, Higuchi M, Kaasinen V, Masellis M, Peralta MC, Obeso I, Pineda-pardo JÁ, Cilia R, Ballanger B, Niethammer M, Stoessl JA; on behalf of IPMDS-Neuroimaging Study Group. Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers: Molecular Imaging in Parkinsonian Disorders. Mov Disord 2017;32:181-92. [DOI: 10.1002/mds.26907] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 10.6] [Reference Citation Analysis]
180 Calabresi P, Tambasco N. Movement disorders in 2016: from genes to phenotypes. The Lancet Neurology 2017;16:9-10. [DOI: 10.1016/s1474-4422(16)30345-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
181 Standaert DG, Geldmacher DS. Glucocerebrosidase, Parkinson disease, and the “senses and intellect”: GBA, PD, and “Senses and Intellect”. Ann Neurol 2016;80:660-1. [DOI: 10.1002/ana.24808] [Reference Citation Analysis]
182 Mistry PK, Lopez G, Schiffmann R, Barton NW, Weinreb NJ, Sidransky E. Gaucher disease: Progress and ongoing challenges. Mol Genet Metab 2017;120:8-21. [PMID: 27916601 DOI: 10.1016/j.ymgme.2016.11.006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 71] [Article Influence: 10.8] [Reference Citation Analysis]